Transcatheter tricuspid valve replacement effectively reduces severe tricuspid regurgitation and induces reverse right ventricular remodeling, despite risks of conduction and bleeding complications.
This consensus document provides expert recommendations for the periprocedural management, anticoagulation strategies, and long-term follow-up of patients undergoing transcatheter tricuspid valve replacement.
Transcatheter tricuspid valve replacement (TTVR) has emerged as a promising intervention for the treatment of severe tricuspid regurgitation with complex valve morphology. This consensus document provides a comprehensive overview of the current state of orthotopic TTVR, focusing on patient selection, procedural details, and follow-up care. Clinical outcomes from initial studies and compassionate use cases are discussed, highlighting the effectiveness of TTVR in reducing tricuspid regurgitation, inducing reverse right ventricular remodeling, and enhancing patients' quality of life. This review paper also addresses potential complications and challenges associated with TTVR, such as new-onset conduction disturbances, bleeding complications, and afterload mismatch, and provides expert recommendations for the periprocedural management, anticoagulation strategies, and long-term follow-up. With the commercial approval of the first TTVR system in the United States and Europe, it intends to serve as a reference for clinicians and researchers involved in the evolving field of transcatheter tricuspid valve interventions.
Hausleiter et al. (Sat,) conducted a review in Severe tricuspid regurgitation with complex valve morphology. Transcatheter tricuspid valve replacement (TTVR) was evaluated. Transcatheter tricuspid valve replacement effectively reduces severe tricuspid regurgitation and induces reverse right ventricular remodeling, despite risks of conduction and bleeding complications.